United States · Bill · HR
H.R. 1143 (119th)
Medicare IVIG Access Enhancement Act of 2025
Introduced
7 February 2025
Last action
—
Status
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
—
Subjects
Discovery layer
Source updated
5 November 2025
Summary
Medicare IVIG Access Enhancement Act of 2025 This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in House
Introduced in House
Introduced in House · EN · 7 February 2025
Introduced in House
summary · EN · 7 February 2025
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/house-bill/1143
- Open data entity: https://api.congress.gov/v3/bill/119/hr/1143